Patrizia Giannatempo, Medical Oncology Consultant at the National Cancer Institute (INT) in Milan, shared a post on X:
“ASCO25 Zelenectide vedotin (BT8009) + pembro: ORR 65% (25% CR) in 1L cis-ineligible la/mUC (incl. PS 2).
Bicycle toxin conjugate (small peptide) targeting Nectin-4, with renal clearance (vs hepatic for EV). Encouraging tolerability.”
Title: Phase 1/2 Duravelo-1 study: Preliminary results of nectin-4–targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.
Authors: Patrizia Giannatempo, Matthew Galsky, Ignacio Duran, Valentina Boni, Andrea Necchi, Antoine Italiano, Meredith McKean, Loic Verlingue, Rama Balaraman, Leslie DeMars, Kate Josephs, Cong Xu, Oscar Reig Torras
Read the Full Article.